KYMR Stock Overview
A biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Kymera Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$42.84 |
| 52 Week High | US$53.27 |
| 52 Week Low | US$18.89 |
| Beta | 2.22 |
| 11 Month Change | -7.99% |
| 3 Month Change | -6.56% |
| 1 Year Change | 117.02% |
| 33 Year Change | -23.85% |
| 5 Year Change | n/a |
| Change since IPO | 28.80% |
Recent News & Updates
Recent updates
Earnings Update: Kymera Therapeutics, Inc. (NASDAQ:KYMR) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts
Nov 04
Kymera's Protein Degradation Technology: A Promising Bet For Long-Term Biotech Investors
Oct 06Analysts Are Upgrading Kymera Therapeutics, Inc. (NASDAQ:KYMR) After Its Latest Results
Aug 11Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) 27% Share Price Surge Not Quite Adding Up
Jul 14Shareholders Will Probably Hold Off On Increasing Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) CEO Compensation For The Time Being
Jun 12We Think Kymera Therapeutics (NASDAQ:KYMR) Can Easily Afford To Drive Business Growth
May 03Kymera Therapeutics: Advancing Into Phase 2 With Partner Sanofi - I Still Have Faith
Mar 21Kymera Therapeutics, Inc. (NASDAQ:KYMR) Released Earnings Last Week And Analysts Lifted Their Price Target To US$47.43
Feb 25Optimistic Investors Push Kymera Therapeutics, Inc. (NASDAQ:KYMR) Shares Up 39% But Growth Is Lacking
Feb 17Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) Shares Climb 33% But Its Business Is Yet to Catch Up
Dec 29We Think Kymera Therapeutics (NASDAQ:KYMR) Needs To Drive Business Growth Carefully
Nov 06Industry Analysts Just Made A Substantial Upgrade To Their Kymera Therapeutics, Inc. (NASDAQ:KYMR) Revenue Forecasts
Aug 31Here's Why We're Not Too Worried About Kymera Therapeutics' (NASDAQ:KYMR) Cash Burn Situation
Aug 04Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) Share Price Not Quite Adding Up
May 21We're Hopeful That Kymera Therapeutics (NASDAQ:KYMR) Will Use Its Cash Wisely
Apr 16Companies Like Kymera Therapeutics (NASDAQ:KYMR) Are In A Position To Invest In Growth
Dec 28Shareholder Returns
| KYMR | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -11.9% | -7.5% | -1.2% |
| 1Y | 117.0% | 14.1% | 30.4% |
Return vs Industry: KYMR exceeded the US Biotechs industry which returned 14.1% over the past year.
Return vs Market: KYMR exceeded the US Market which returned 30.4% over the past year.
Price Volatility
| KYMR volatility | |
|---|---|
| KYMR Average Weekly Movement | 7.2% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: KYMR has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: KYMR's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 184 | Nello Mainolfi | www.kymeratx.com |
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus.
Kymera Therapeutics, Inc. Fundamentals Summary
| KYMR fundamental statistics | |
|---|---|
| Market cap | US$2.77b |
| Earnings (TTM) | -US$167.47m |
| Revenue (TTM) | US$87.56m |
31.7x
P/S Ratio-16.6x
P/E RatioIs KYMR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KYMR income statement (TTM) | |
|---|---|
| Revenue | US$87.56m |
| Cost of Revenue | US$221.40m |
| Gross Profit | -US$133.84m |
| Other Expenses | US$33.64m |
| Earnings | -US$167.47m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.59 |
| Gross Margin | -152.85% |
| Net Profit Margin | -191.26% |
| Debt/Equity Ratio | 0% |
How did KYMR perform over the long term?
See historical performance and comparison